
Biotech firm AmacaThera has struck a worldwide deal with Pacira BioSciences to licence its long-acting non-opioid pain management platform, AMT-143, receiving a US$5 million upfront payment and up to US$225 million in future milestones. The agreement underscores AmacaThera's tunable hydrogel drug-delivery technology and sets the stage for Pacira to fund development, manufacturing and commercialisation of AMT-143, targeted for 2026.
Click here for DetailsAmacaThera’s clinically validated hydrogel drug delivery platform seamlessly integrates two well-established, biocompatible polymers, hyaluronic acid and methylcellulose, into a proprietary formulation. This innovative injectable hydrogel enables precise, localized, and sustained delivery of therapeutics, ensuring long-acting release exactly where it is needed. The platform is broadly compatible with a diverse array of therapeutic agents, including small molecules, biologics, enzymes, and cells. Its tunability allows for the fine adjustment of drug release parameters, such as rate, duration, and timing tailored to the unique requirements of each clinical application.
Next generation hydrogel-based drug delivery platform that enables precise, localized, and long-acting drug release for a wide range of therapeutics.
Tunable platform works with small molecules, biologics, antibodies, peptides, nanoparticles, and cells, and is tailored for various clinical needs from post-surgical pain to oncology and beyond.
Proven safety and efficacy through preclinical models and Phase 1 human trials, minimizing regulatory risk.
Simple "mix and fill" process reduces production costs and easily scales to meet global demand.
Partner with pharma companies to advance products, generating value through upfront payments, milestones, and royalties while accelerating product development.
AmacaThera seeks to partner with like minded companies to co-develop new, exciting products that provide on-time, on-target therapeutic solutions.
Get in touch